Sino Biopharmaceutical Limited (SMZ1.F)

0,3338 +0,0136 (+4,25%) A partir del 12:17PM CEST. Mercado abierto.

Sino Biopharmaceutical Limited

Unit 09, Office Tower
41st Floor, Room 4109 Convention Plaza 1 Harbour Road
Wan Chai
Hong Kong
852 2802 9886
https://www.sinobiopharm.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 25.806

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Ms. Y. Y. Tse	Executive Chairwoman of the Board	6,52M	N/A	1992
Mr. Eric S. Y. Tse	CEO & Executive Director	6,52M	N/A	1996
Mr. Ping Tse	Founder & Senior Executive Vice Chairman	6,5M	N/A	1952
Ms. Cheung Ling Cheng	Executive Vice Chairwoman of the Board	5,66M	N/A	1964
Mr. Zhoushan Tian	Executive Director	250,52k	N/A	1964
Mr. Hsin Tse	Senior VP & Executive Director	841,89k	N/A	1970
Ms. Chun Ling Li	Chief Financial Officer	N/A	N/A	1972
Mr. Song Jin	Vice President of Public Affairs, Medicines Policies & ESG	N/A	N/A	1976
Mr. Sean Chen	Chief Strategy Officer	N/A	N/A	1978
Orphanides George	Chief Scientific Advisor of invoX	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji; cardio-cerebral vascular medicines, such as irbesartan and hydrochlorothiazide tablets under the brand Yilunping and beraprost sodium tablets under the brand Kaina; and biosimilar medicines comprising adalimumab solution for injection under the brand Taibowei. In addition, the company develops oncology drugs, include benmelstobart, D-1553, TQ-B3139, and TQ-B3101; liver disease drugs, such as Lanifibranor and TQA2225/AP025; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Gobierno corporativo

El ISS Governance QualityScore de Sino Biopharmaceutical Limited, a día 1 de junio de 2024, es 6. Las puntuaciones base son Auditoría: 4; Tablero: 1; Derechos de los accionistas: 7; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.